or Try an Advanced Search...

    Technical Analysis for JANX - Janux Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 47.01 -0.99% -0.47
    JANX closed down 0.9 percent on Wednesday, May 15, 2024, on 1.2 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical JANX trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion -0.99%
    Gapped Up Strength -0.99%
    Oversold Stochastic Weakness -0.99%
    Stochastic Reached Oversold Weakness -1.88%
    Multiple of Ten Bearish Other -1.88%
    Outside Day Range Expansion -1.88%
    Wide Bands Range Expansion -1.88%
    Oversold Stochastic Weakness -1.88%
    Hammer Candlestick Bullish -5.96%
    Lizard Bullish Bullish Day Trade Setup -5.96%
    Older End-of-Day Signals for JANX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 1 hour ago
    60 Minute Opening Range Breakout about 4 hours ago
    Up 1% about 4 hours ago
    Fell Below Previous Day's Low about 5 hours ago
    Down 1% about 5 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    JANX Chart by TradingView
    Basic chart:

    Profile

    Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation

    Is JANX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 9 We're Not Very Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Rate
    May 8 Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates
    May 7 Janux Therapeutics GAAP EPS of -$0.30 beats by $0.03
    May 7 Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
    May 2 Janux Therapeutics gains amid renewed takeover speculation
    Apr 30 Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength
    Apr 29 Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal
    Apr 17 Take the Money and Run: 3 Overbought Stocks to Sell ASAP
    Apr 16 Janux a new buy at Jones on lead assets for solid tumors
    Apr 16 These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
    See more JANX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 65.6
    52 Week Low 5.65
    Average Volume 767,759
    200-Day Moving Average 19.83
    50-Day Moving Average 45.73
    20-Day Moving Average 53.13
    10-Day Moving Average 55.25
    Average True Range 4.63
    RSI (14) 44.75
    ADX 31.56
    +DI 23.61
    -DI 21.08
    Chandelier Exit (Long, 3 ATRs) 51.70
    Chandelier Exit (Short, 3 ATRs) 58.61
    Upper Bollinger Bands 64.78
    Lower Bollinger Band 41.49
    Percent B (%b) 0.26
    BandWidth 43.82
    MACD Line 1.65
    MACD Signal Line 3.45
    MACD Histogram -1.8049
    Fundamentals Value
    Market Cap 2.19 Billion
    Num Shares 46.2 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -32.30
    Price-to-Sales 51.42
    Price-to-Book 1.22
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 51.28
    Resistance 3 (R3) 51.65 50.76 50.64
    Resistance 2 (R2) 50.76 49.79 50.57 50.43
    Resistance 1 (R1) 49.12 49.20 48.68 48.75 50.22
    Pivot Point 48.23 48.23 48.01 48.04 48.23
    Support 1 (S1) 46.59 47.26 46.15 46.22 44.74
    Support 2 (S2) 45.70 46.67 45.51 44.53
    Support 3 (S3) 44.06 45.70 44.32
    Support 4 (S4) 43.69